Weekly Recap | AKESO -11.54%, most brokers rate it buy

LongbridgeAII'm LongbridgeAI, I can summarize articles.

The Week

Akeso (9926.HK) fell 11.54% this week to close at HK$56.70, while the Hang Seng Index dropped 5.65%, leaving the stock about 5.89 percentage points behind the benchmark. The week opened with a brief spike: Monday (16 Nov) started at HK$63.00 and touched HK$66.70 before reversing to close at HK$61.90. Tuesday (17 Nov) slid to HK$59.00, Wednesday (18 Nov) bounced to HK$61.00, and Thursday (19 Nov) sank to a low of HK$56.20 before settling at HK$56.70, just above the 60-day range low of HK$56.10. Weekly amplitude came to 16.67%, with average daily volume of roughly 17.7m shares, 67.15% above the median, pointing to a high-volume sell-off. The closing price sits well below both the 20-day (HK$78.18) and 60-day (HK$90.46) moving averages.

Key Events

The dominant thread this week was the fallout from the US FDA’s complete response letter for ivonescimab in lung cancer, followed by the company’s buyback response. On Monday (16 Nov), news of the CRL hit the tape and Akeso briefly plunged as much as 32%, closing down over 22%. The company issued a statement that afternoon saying the FDA letter could explain the unusual share-price move. The same day, China approved gumokimab for active ankylosing spondylitis, though that did not offset the selling. On Tuesday (17 Nov), China accepted Akeso’s application for ivonescimab in biliary tract cancer, and the company proposed additional on-market share purchases. The trustee then executed purchases of about 200,000 shares on both Wednesday (18 Nov) and Thursday (19 Nov). Across the week, the company paired active buybacks with regulatory setbacks, but market attention remained fixed on the US rejection.

Analyst Ratings

The analyst picture is divided. As of 20 Nov 2026, 23 brokers cover the stock: 17 rate it buy, 4 overweight, and 2 hold, with no underweight or sell ratings. The consensus recommendation is strong buy, with a consensus target of HK$137.41, roughly 142.34% above the current price. Targets range widely from HK$73.88 to HK$225.90, reflecting disagreement over the regulatory path. Akeso ranks second among 52 biotech peers on rating strength. During the week, CMB International, SPDB and others kept buy ratings, while Nomura cut to neutral with a HK$94 target, Citi trimmed to HK$163, and Daiwa cut to HK$120 but reiterated buy.

The Week Ahead

The key item next week is Akeso’s Q3 FY2026 results, due after market close on Friday, 27 Nov. Investors will be watching for updates on domestic commercialisation after the US setback, overseas clinical data, and the pace of the buyback programme already announced. The China application for ivonescimab in biliary tract cancer is also now under review, with further regulatory milestones ahead.

In Short

Akeso fell sharply this week on heavy volume, with the market still absorbing the US approval rejection. At the same time, the company has been buying back shares, and the consensus target remains well above spot, though the wide target range signals real uncertainty over the regulatory path. The stock trades at a negative P/E and 5.46x P/B, with mixed flows from large and small traders in the latest session. The next data point is the Q3 report: whether it can reboot the narrative, alongside further buyback and regulatory news, will shape the near-term direction.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.

Source: Weekly Review The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.